Publications

Selected Publications

  1. Chemaitelly H, Tang P, Coyle P, Yassine HM, Al-Khatib HA, Smatti MK, Hasan MR, Ayoub HH, Altarawneh HN, Al-Kanaani Z, Al-Kuwari E, Jeremijenko A, Kaleeckal AH, Latif AN, Shaik RM, Abdul-Rahim HF, Nasrallah GK, Al-Kuwari MG, Butt AA, Al-Romaihi HE, Al-Thani MH, Al-Khal A, Bertollini R, Abu-Raddad LJ, National Study Group for Covid-Epidemiology. Protection against reinfection with the Omicron BA.2.75 subvariant. N Engl J Med 2023;388:665-7. https://doi.org/10.1056/nejmc2214114
    Corresponding author
  2. Chemaitelly H, AlMukdad S, Ayoub HH, Altarawneh HN, Coyle P, Tang P, Yassine HM, Al-Khatib HA, Smatti MK, Hasan MR, Al-Kanaani Z, Al-Kuwari E, Jeremijenko A, Kaleeckal AH, Latif AN, Shaik RM, Abdul-Rahim HF, Nasrallah GK, Al-Kuwari MG, Al-Romaihi HE, Butt AA, Al-Thani MH, Al-Khal A, Bertollini R, Abu-Raddad LJ. Covid-19 vaccine protection among children and adolescents in Qatar. N Engl J Med 2022;387:1865-76. https://doi.org/10.1056/nejmoa2210058
  3. Chemaitelly H, Ayoub HH, Tang P, Hasan MR, Coyle P, Yassine HM, Al-Khatib HA, Smatti MK, Al-Kanaani Z, Al-Kuwari E, Jeremijenko A, Kaleeckal AH, Latif AN, Shaik RM, Abdul-Rahim HF, Nasrallah GK, Al-Kuwari MG, Butt AA, Al-Romaihi HE, Al-Thani MH, Al-Khal A, Bertollini R, Abu-Raddad LJ. Immune imprinting and protection against repeat reinfection with SARS-CoV-2. N Engl J Med 2022;387:1716-8. https://doi.org/10.1056/nejmc2211055
    Corresponding author
  4. Chemaitelly H, Tang P, Hasan MR, AlMukdad S, Yassine HM, Benslimane FM, Al Khatib HA, Coyle P, Ayoub HH, Al Kanaani Z, Al Kuwari E, Jeremijenko A, Kaleeckal AH, Latif AN, Shaik RM, Abdul Rahim HF, Nasrallah GK, Al Kuwari MG, Al Romaihi HE, Butt AA, Al-Thani MH, Al Khal A, Bertollini R, Abu-Raddad LJ. Waning of BNT162b2 vaccine protection against SARS-CoV-2 infection in Qatar. N Engl J Med. 2021 Dec 9;385(24):e83. https://doi.org/10.1056/NEJMoa2114114
  5. Chemaitelly H, Bertollini R, Abu-Raddad LJ. Efficacy of natural immunity against SARS-CoV-2 reinfection with the Beta variant. N Engl J Med. 2021 Dec 30;385(27):2585-6. https://doi.org/10.1056/NEJMc2110300
  6. Altarawneh H,* Chemaitelly H,* Hasan MR, Ayoub HH, Qassim S, AlMukdad S, Coyle P, Yassine HM, Al-Khatib HA, Benslimane FM, Al-Kanaani Z, Al-Kuwari E, Jeremijenko A, Kaleeckal AH, Latif AN, Shaik RM, Abdul-Rahim HF, Nasrallah GK, Al-Kuwari MG, Butt AA, Al-Romaihi HE, Al-Thani MH, Al-Khal A, Bertollini R, Tang P, Abu-Raddad LJ. Protection against the Omicron variant from previous SARS-CoV-2 infection. N Engl J Med 2022;386:1288-90. https://doi.org/10.1056/nejmc2200133
    *Authors contributed equally to the work
  7. Altarawneh HN, Chemaitelly H, Ayoub HH, Tang P, Hasan MR, Yassine HM, Al-Khatib HA, Smatti MK, Coyle P, Al-Kanaani Z, Al-Kuwari E, Jeremijenko A, Kaleeckal AH, Latif AN, Shaik RM, Abdul-Rahim HF, Nasrallah GK, Al-Kuwari MG, Butt AA, Al-Romaihi HE, Al-Thani MH, Al-Khal A, Bertollini R, Abu-Raddad LJ. Effects of previous infection and vaccination on symptomatic Omicron infections. N Engl J Med 2022;387:21-34. https://doi.org/10.1056/nejmoa2203965
    Corresponding author
  8. Abu-Raddad LJ, Chemaitelly H, Ayoub HH, AlMukdad S, Yassine HM, Al-Khatib HA, Smatti MK, Tang P, Hasan MR, Coyle P, Al-Kanaani Z, Al-Kuwari E, Jeremijenko A, Kaleeckal AH, Latif AN, Shaik RM, Abdul-Rahim HF, Nasrallah GK, Al-Kuwari MG, Butt AA, Al-Romaihi HE, Al-Thani MH, Al-Khal A, Bertollini R. Effect of mRNA vaccine boosters against SARS-CoV-2 omicron infection in Qatar. N Engl J Med 2022;386:1804-16. https://doi.org/10.1056/nejmoa2200797
  9. Abu-Raddad LJ, Chemaitelly H, Butt AA. Effectiveness of the BNT162b2 Covid-19 vaccine against the B.1.1.7 and B.1.351 variants. N Engl J Med. 2021 Jul 8;385(2):187-9. https://doi.org/10.1056/NEJMc2104974
  10. Abu-Raddad LJ, Chemaitelly H, Bertollini R. Severity of SARS-CoV-2 reinfections as compared with primary infections. N Engl J Med. 2021 Dec 23;385(26):2487-9. https://doi.org/10.1056/NEJMc2108120
  11. Abu-Raddad LJ, Chemaitelly H, Bertollini R. Waning mRNA-1273 vaccine effectiveness against SARS-CoV-2 infection in Qatar. N Engl J Med 2022;386:1091-3. https://doi.org/10.1056/NEJMc2119432
  12. Abu-Raddad LJ, Chemaitelly H, Bertollini R. Effectiveness of mRNA-1273 and BNT162b2 vaccines in Qatar. N Engl J Med 2022;386:799-800. doi: 10.1056/NEJMc2117933. https://doi.org/10.1056/NEJMc2117933
  13. Chemaitelly H, Ayoub HH, AlMukdad S, Coyle P, Tang P, Yassine HM, Al-Khatib HA, Smatti MK, Hasan MR, Al-Kanaani Z, Al-Kuwari E, Jeremijenko A, Kaleeckal AH, Latif AN, Shaik RM, Abdul-Rahim HF, Nasrallah GK, Al-Kuwari MG, Butt AA, Al-Romaihi HE, Al-Thani MH, Al-Khal A, Bertollini R, Abu-Raddad LJ. Protection from previous natural infection compared with mRNA vaccination against SARS-CoV-2 infection and severe COVID-19 in Qatar: a retrospective cohort study. Lancet Microbe 2022;3:e944-e955. https://doi.org/10.1016/s2666-5247(22)00287-7
    Corresponding author
  14. 14. Chemaitelly H, Ayoub HH, Tang P, Coyle P, Yassine HM, Al Thani AA, Al-Khatib HA, Hasan MR, Al-Kanaani Z, Al-Kuwari E, Jeremijenko A, Kaleeckal AH, Latif AN, Shaik RM, Abdul-Rahim HF, Nasrallah GK, Al-Kuwari MG, Butt AA, Al-Romaihi HE, Al-Thani MH, Al-Khal A, Bertollini R, Faust JS, Abu-Raddad LJ. Long-term COVID-19 booster effectiveness by infection history and clinical vulnerability and immune imprinting: a retrospective population-based cohort study. The Lancet infectious diseases 2023;23:816-27. https://doi.org/10.1016/s1473-3099(23)00058-0
  15. Chemaitelly H†, Ayoub HH, Coyle P, Tang P, Yassine HM, Al Thani AA, Al-Khatib HA, Hasan MR, Al-Kanaani Z, Al-Kuwari E, Jeremijenko A, Kaleeckal AH, Latif AN, Shaik RM, Abdul-Rahim HF, Nasrallah GK, Al-Kuwari MG, Al-Romaihi HE, Butt AA, Al-Thani MH, Al-Khal A, Bertollini R, Abu-Raddad LJ. BNT162b2 antigen dose and SARS-CoV-2 omicron infection in adolescents. Lancet Infect Dis 2023;23:276-7. https://doi.org/10.1016/s1473-3099(23)00005-1
    Corresponding author
  16. Chemaitelly H, Yassine HM, Benslimane FM, Al Khatib HA, Tang P, Hasan MR, Malek JA, Coyle P, Ayoub HH, Al Kanaani Z, Al Kuwari E, Jeremijenko A, Kaleeckal AH, Latif AN, Shaik RM, Abdul Rahim HF, Nasrallah GK, Al Kuwari MG, Al Romaihi HE, Al-Thani MH, Al Khal A, Butt AA, Bertollini R, Abu-Raddad LJ. mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar. Nat Med. 2021 Sep;27(9):1614-21. https://doi.org/10.1038/s41591-021-01446-y
  17. Tang P*, Hasan MR*, Chemaitelly H*, Yassine HM, Benslimane FM, Al Khatib HA, AlMukdad S, Coyle P, Ayoub HH, Al Kanaani Z, Al Kuwari E, Jeremijenko A, Kaleeckal AH, Latif AN, Shaik RM, Abdul Rahim HF, Nasrallah GK, Al Kuwari MG, Al Romaihi HE, Butt AA, Al-Thani MH, Al Khal A, Bertollini R, Abu-Raddad LJ. BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar. Nat Med. 2021 Dec;27(12):2136-43. https://doi.org/10.1038/s41591-021-01583-4
    *Authors contributed equally to the work
  18. Chemaitelly H, Ayoub HH, Tang P, Coyle PV, Yassine HM, Al Thani AA, Al-Khatib HA, Hasan MR, Al-Kanaani Z, Al-Kuwari E, Jeremijenko A, Kaleeckal AH, Latif AN, Shaik RM, Abdul-Rahim HF, Nasrallah GK, Al-Kuwari MG, Butt AA, Al-Romaihi HE, Al-Thani MH, Al-Khal A, Bertollini R, Abu-Raddad LJ. History of primary-series and booster vaccination and protection against Omicron reinfection. Sci Adv 2023;9:eadh0761. https://doi.org/10.1126/sciadv.adh0761
    Corresponding author
  19. Chemaitelly H, Ayoub HH, AlMukdad S, Coyle P, Tang P, Yassine HM, Al-Khatib HA, Smatti MK, Hasan MR, Al-Kanaani Z, Al-Kuwari E, Jeremijenko A, Kaleeckal AH, Latif AN, Shaik RM, Abdul-Rahim HF, Nasrallah GK, Al-Kuwari MG, Butt AA, Al-Romaihi HE, Al-Thani MH, Al-Khal A, Bertollini R, Abu-Raddad LJ. Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA.1 and BA.2 subvariants in Qatar. Nat Commun 2022;13:3082. https://doi.org/10.1038/s41467-022-30895-3
  20. Chemaitelly H, Ayoub HH, Coyle P, Tang P, Yassine HM, Al-Khatib HA, Smatti MK, Hasan MR, Al-Kanaani Z, Al-Kuwari E, Jeremijenko A, Kaleeckal AH, Latif AN, Shaik RM, Abdul-Rahim HF, Nasrallah GK, Al-Kuwari MG, Butt AA, Al-Romaihi HE, Al-Thani MH, Al-Khal A, Bertollini R, Abu-Raddad LJ. Protection of Omicron sub-lineage infection against reinfection with another Omicron sub-lineage. Nat Commun 2022;13:4675. https://doi.org/10.1038/s41467-022-32363-4
    Corresponding author
  21. Abu-Raddad LJ, Chemaitelly H, Ayoub HH, Yassine HM, Benslimane FM, Al Khatib HA, Tang P, Hasan MR, Coyle P, Al Kanaani Z, Al Kuwari E, Jeremijenko A, Kaleeckal AH, Latif AN, Shaik RM, Abdul Rahim HF, Nasrallah GK, Al Kuwari MG, Butt AA, Al Romaihi HE, Al-Thani MH, Al Khal A, Bertollini R. Association of prior SARS-CoV-2 infection with risk of breakthrough infection following mRNA vaccination in Qatar. JAMA. 2021 Nov 16;326(19):1930-9. https://doi.org/10.1001/jama.2021.19623
  22. Bertollini R, Chemaitelly H, Yassine HM, Al-Thani MH, Al-Khal A, Abu-Raddad LJ. Associations of vaccination and of prior infection with positive PCR test results for SARS-CoV-2 in airline passengers arriving in Qatar. JAMA. 2021 Jul 13;326(2):185-8. https://doi.org/10.1001/jama.2021.9970
  23. Abu-Raddad LJ, Chemaitelly H, Ayoub HH, Coyle P, Malek JA, Ahmed AA, Mohamoud YA, Younuskunju S, Tang P, Al Kanaani Z, Al Kuwari E, Butt AA, Jeremijenko A, Kaleeckal AH, Latif AN, Shaik RM, Abdul Rahim HF, Nasrallah GK, Yassine HM, Al Kuwari MG, Al Romaihi HE, Al-Thani MH, Al Khal A, Bertollini R. Introduction and expansion of the SARS-CoV-2 B.1.1.7 variant and reinfections in Qatar: a nationally representative cohort study. PLoS Med. 2021 Dec;18(12):e1003879. https://doi.org/10.1371/journal.pmed.1003879
  24. Chemaitelly H, Ayoub HH, Omori R, El Feki S, Hermez JG, Weiss HA, Abu-Raddad LJ. HIV incidence and impact of interventions among female sex workers and their clients in the Middle East and north Africa: a modelling study. Lancet HIV 2022;9:e496-e505. https://doi.org/10.1016/s2352-3018(22)00100-x
    Corresponding author
  25. Smolak A*, Chemaitelly H*, Hermez JG, Low N, Abu-Raddad LJ. Epidemiology of chlamydia trachomatis in the Middle East and North Africa: a systematic review, meta-analysis, and meta-regression. Lancet Glob Health. 2019 Sep;7(9):e1197-e225. https://doi.org/10.1016/s2214-109x(19)30279-7
    *Authors contributed equally to the work
  26. Chemaitelly H, Coyle P, Kacem MAB, Ayoub HH, Tang P, Hasan MR, Yassine HM, Al Thani AA, Al-Kanaani Z, Al-Kuwari E, Jeremijenko A, Kaleeckal AH, Latif AN, Shaik RM, Abdul-Rahim HF, Nasrallah GK, Al-Kuwari MG, Butt AA, Al-Romaihi HE, Al-Thani MH, Al-Khal A, Bertollini R, Abu-Raddad LJ. Protection of natural infection against reinfection with SARS-CoV-2 JN.1 variant. J Travel Med 2024;31:taae053. https://doi.org/10.1093/jtm/taae053
    Corresponding author
  27. Chemaitelly H, Ayoub HH, AlMukdad S, Faust JS, Tang P, Coyle P, Yassine HM, Al Thani AA, Al-Khatib HA, Hasan MR, Al-Kanaani Z, Al-Kuwari E, Jeremijenko A, Kaleeckal AH, Latif AN, Shaik RM, Abdul-Rahim HF, Nasrallah GK, Al-Kuwari MG, Butt AA, Al-Romaihi HE, Al-Thani MH, Al-Khal A, Bertollini R, Abu-Raddad LJ. Bivalent mRNA-1273.214 vaccine effectiveness against SARS-CoV-2 omicron XBB* infections. J Travel Med 2023;30:taad106. https://doi.org/10.1093/jtm/taad106
    Corresponding author
  28. Chemaitelly H, Nagelkerke N, Ayoub HH, Coyle P, Tang P, Yassine HM, Al-Khatib HA, Smatti MK, Hasan MR, Al-Kanaani Z, Al-Kuwari E, Jeremijenko A, Kaleeckal AH, Latif AN, Shaik RM, Abdul-Rahim HF, Nasrallah GK, Al-Kuwari MG, Butt AA, Al-Romaihi HE, Al-Thani MH, Al-Khal A, Bertollini R, Abu-Raddad LJ. Duration of immune protection of SARS-CoV-2 natural infection against reinfection. J Travel Med 2022;29:taac109. doi: 10.1093/jtm/taac109. https://doi.org/10.1093/jtm/taac109
    Corresponding author
  29. Chemaitelly H, Mahmud S, Chaabna K, Kouyoumjian SP, Mumtaz GR, Abu Raddad LJ. Epidemiology of hepatitis C virus in the WHO Eastern Mediterranean Region: implications for strategic action. Cairo, Egypt: World Health Organization. Regional Office for the Eastern Mediterranean; 2020. https://applications.emro.who.int/docs/9789290222866-eng.pdf?ua=1
  30. Mumtaz GR*, Chemaitelly H*, AlMukdad S, Osman A, Fahme S, Rizk NA, El Feki S, Abu-Raddad LJ. Status of the HIV epidemic in key populations in the Middle East and North Africa: knowns and unknowns. Lancet HIV 2022;9:e506-e16. https://doi.org/10.1016/s2352-3018(22)00093-5
    *Authors contributed equally to the work
  31. Chemaitelly H, Weiss HA, Smolak A, Majed E, Abu-Raddad LJ. Epidemiology of treponema pallidum, chlamydia trachomatis, neisseria gonorrhoeae, trichomonas vaginalis, and herpes simplex virus type 2 among female sex workers in the Middle East and North Africa: systematic review and meta-analytics. J Glob Health. 2019 Dec;9(2):020408. https://doi.org/10.7189/jogh.09.020408
    Corresponding author
  32. 3Chemaitelly H, Weiss HA, Calvert C, Harfouche M, Abu-Raddad LJ. HIV epidemiology among female sex workers and their clients in the Middle East and North Africa: systematic review, meta-analyses, and meta-regressions. BMC Med. 2019 Jun 24;17(1):119. https://doi.org/10.1186/s12916-019-1349-y
  33. Chemaitelly H, Mahmud S, Kouyoumjian SP, Al-Kanaani Z, Hermez JG, Abu-Raddad LJ. Who to test for hepatitis C virus in the Middle East and North Africa?: pooled analyses of 2,500 prevalence measures, including 49 million tests. Hepatol Commun. 2019 Mar;3(3):325-39. https://doi.org/10.1002/hep4.1310
    Corresponding author
  34. Chemaitelly H, Majed A, Abu-Hijleh F, Blondeel K, Matsaseng TC, Kiarie J, Toskin I, Abu-Raddad LJ. Global epidemiology of neisseria gonorrhoeae in infertile populations: systematic review, meta-analysis and metaregression. Sex Transm Infect. 2021 Mar;97(2):157-69. https://doi.org/10.1136/sextrans-2020-054515

Full List of publications PubMed